Regulatory guidance enables safe and effective use of AI tools in medicine development and evaluation across the medicine lifecycle.
On 2026-08-13, a peer-reviewed article reported a European-wide survey to set regulatory science research priorities for AI use in the medicine lifecycle. Authors developed 28 research questions across seven domains and collected 273 responses from regulators, industry, patients and consumers, academics, and healthcare professionals, finding convergence in rankings across groups.
- Impact 30%
- 49
- Evidence 25%
- 95
- Scale 20%
- 85
- Confidence 15%
- 87
- Recency 10%
- 89
Updated Aug 15, 2026 · TRV-2026-0772
ace